RAM
PRTK

Roumell Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Roumell Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-340,323
Closed -$1.37M – 25
2019
Q4 		$1.37M Sell
340,323
-413,559
-55% -$1.43M 3.14% 11
2019
Q3 		$3.26M Buy
753,882
+75,087
+11% +$300K 7.69% 6
2019
Q2 		$2.71M Buy
678,795
+21,099
+3% +$100K 6.41% 6
2019
Q1 		$3.52M Buy
657,696
+207,290
+46% +$1.34M 8.58% 5
2018
Q4 		$2.31M Buy
450,406
+198,640
+79% +$1.51M 4.78% 10
2018
Q3 		$2.44M Sell
251,766
-5,764
-2% -$58.1K 4.48% 11
2018
Q2 		$2.63M Buy
257,530
+60,183
+30% +$681K 5.85% 8
2018
Q1 		$2.57M Buy
197,347
+96,668
+96% +$1.44M 5.65% 8
2017
Q4 		$1.8M Sell
100,679
-720
-0.7% -$15K 3.86% 13
2017
Q3 		$2.54M Sell
101,399
-156,349
-61% -$3.64M 5.99% 8
2017
Q2 		$6.21M Buy
257,748
+13,765
+6% +$304K 13.71% 2
2017
Q1 		$4.7M Sell
243,983
-68,492
-22% -$1.08M 12.84% 2
2016
Q4 		$4.81M Buy
312,475
+27,664
+10% +$359K 11.95% 2
2016
Q3 		$3.71M Sell
284,811
-5,325
-2% -$70.6K 11.32% 4
2016
Q2 		$4.04M Buy
290,136
+73,008
+34% +$1.07M 9.16% 4
2016
Q1 		$3.29M Buy
217,128
+17,573
+9% +$269K 8.36% 5
2015
Q4 		$3.79M Sell
199,555
-2,290
-1% -$43.7K 8.77% 5
2015
Q3 		$3.83M Sell
201,845
-5,858
-3% -$146K 7.78% 6
2015
Q2 		$5.35M Sell
207,703
-4,735
-2% -$134K 9.43% 4
2015
Q1 		$6.64M Sell
212,438
-19,040
-8% -$547K 10.68% 4
2014
Q4 		$8.92M Buy
231,478
+44,035
+23% +$1.05M 11.28% 4
2014
Q3 		$4.55M Buy
187,443
+25,594
+16% +$668K 5.11% 8
2014
Q2 		$3.87M Sell
161,849
-7,474
-4% -$244K 4.53% 8
2014
Q1 		$6.26M Sell
169,323
-11,290
-6% -$446K 6.29% 6
2013
Q4 		$7.28M Sell
180,613
-7,361
-4% -$313K 7.73% 5
2013
Q3 		$7.17M Sell
187,974
-4,130
-2% -$148K 5.84% 7
2013
Q2 		$6.96M Buy
+192,104
New +$8.23M 4.77% 10

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Roumell Asset Management's PRTK Position: Q1 2020 in Review

Roumell Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 340,323 shares — an estimated $1.37M sold.

Roumell Asset Management first reported a position in PRTK in Q2 2013 and held it in 27 quarters. The position peaked at $8.92M in Q4 2014. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

  • Roumell Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Roumell Asset Management sold 340,323 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.37M.
  • Roumell Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
  • Roumell Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $8.92M in Q4 2014.
  • 85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on Roumell Asset Management's 13F filing for Q1 2020, filed 14 May 2020.